Delighted to have our abstracts accepted for the #LiverMtg19 in #Boston! One oral communication + a poster describing new treatments for portal hypertension and fibrosis in #NASH and #cirrhosis. Looking forward to participating in this great event! AASLD

🆕Discover the unique BarNa model®️. The pre-clinical model of #NASH that mimics pathophysiological features, including advanced fibrosis and portal hypertension, and transcriptomic signature of human #steatohepatitis. Contact us to test your drug in it! mdpi.com/2073-4409/8/9/…

Introducing the BarNa model®️: BLB’s pre-clinical model of #NASH. liver.barcelona/introducing-ba…

Happy to announce the publication of the manuscript “A nutraceutical rich in DHA improves portal hypertension in #cirrhosis” in the journal Nutrients MDPI. Fruit of our collaboration with BrudyLab. Read here the press release: liver.barcelona/a-nutraceutica… #liver

Glad to announce our participation in the upcoming #LiverMtg19 in #Boston!! Our team looks forward to sharing our science and meeting current & new partners! Click to know more 👉🏼 liver.barcelona/barcelona-live…

Dr Gracia-Sancho @jsgracia, presents the effects and underlying mechanisms of 2-week lanifibranor on portal hypertension, hepatic microcirculatory dysfunction and liver fibrosis in pre-clinical advanced cirrhosis. #NASH #LiverMtg19

Great Early Morning Workshop together with Prof. Natalie Török Stanford University the Liver Meeting 2019 #Boston AASLD and excellent presentations from Dr. Pedro Rodrigues Pedro Rodrigues @Biodonostia and Peio Aristu Liver Bioservices Complutense

Today at the #LiverMtg19 Zoe Boyer-Diaz, senior associate scientist, presents the work “hepatic fatty acid profile in chronic #liver #disease: mechanism of injury and novel therapeutic target”. Come by to the posters area and learn about this and other projects of BLB!

Season’s Greetings from the Barcelona Liver Bioservices Team!

A major hurdle in drug development is correctly identifying candidates with low liver toxicity.💊 The "Liver on a Chip" platform by IDIBAPS spin-off and #CaixaImpulse project ExoLiver mimics the liver environment, allowing proper toxicology testing. 👇 caixaimpulse.com/en_US/projects…

#livertwitter 📌 Lanifibranor shown to be effective in NASH in a phase2b RCT of 24 week Rx ✳️ Meets all primary end-points for NASH of both FDA and EMA & reduces fibrosis ✳️ Data in a press release by Inventiva ✳️ The RCT confirms our study in cirrhotic rats at last AASLD

Fresh from the oven! Very happy to share with you our latest collaborative work, just published in Journal of Hepatology: 📖 Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental #cirrhosis Open access ➡️ doi.org/10.1016/j.jhep… #livertwitter

Latest BLB research published in the Journal of Hepatology: liver.barcelona/latest-blb-res…

Happy holidays from the entire BLB’s team! This holiday season we celebrate 5 years developing preclinical research in Hepatology 💫

Our Team Matters Beyond Biomedical Research ➡️ liver.barcelona/barcelona-live…

Warmest holiday greetings to the entire scientific community from BLB! May this festive season bring you joy, inspiration, and breakthrough discoveries. Wishing you a Merry Christmas and a prosperous New Year filled with scientific achievements!🔬#MerryChristmas #HappyNewYear2024

Season Greetings from Barcelona Liver Bioservices! 🎄💫 We’re grateful for all the collaborations in advancing #liver disease #research. Here’s to a successful 2025 filled with new diacoveries and impactful partnerships! 🥂 #HappyHolidays

📢 New study from BLB❗️ Sex-specific differences in liver disease models show males with more fibrosis & inflammation, females with distinct endothelial & fibrotic traits. Part of our R&D, committed to 3Rs & translational research. Free read 🔗 bsd.biomedcentral.com/articles/10.11…